奥法妥木单抗治疗氟达拉滨和阿仑单抗难治性慢性淋巴细胞白血病患者的安全性和疗效。
Safety and efficacy of ofatumumab in patients with fludarabine and alemtuzumab refractory chronic lymphocytic leukaemia.
机构信息
Professor of Haemato-Oncology and Honorary Consultant Physician, Department of Cancer Studies and Molecular Medicine, Leicester University, Hodgkin Building Room 405, Lancaster Road, Leicester LE1 9HN, UK.
出版信息
Ther Adv Hematol. 2012 Aug;3(4):199-207. doi: 10.1177/2040620712445329.
Abstract
There are now many therapeutic CD20 monoclonal antibodies undergoing clinical trials for B-cell malignancy and autoimmune conditions; which is optimal for cancer therapy is not clear. The novel human IgG1 CD20 monoclonal antibody ofatumumab has shown significant activity in difficult to treat patients with chronic lymphocytic leukemia, namely those resistant or refractory to fludarabine and alemtuzumab and has now been licensed for this uncommon indication. This brief review summarizes the clinical data obtained with ofatumumab in CLL in terms of both efficacy and toxicity.
摘要
目前有许多用于治疗 B 细胞恶性肿瘤和自身免疫性疾病的治疗性 CD20 单克隆抗体正在进行临床试验；哪种药物对癌症治疗最有效尚不清楚。新型人源 IgG1 型 CD20 单克隆抗体奥法妥珠单抗在治疗难治或耐药的慢性淋巴细胞白血病患者中显示出显著的疗效，现已被批准用于治疗这一不常见的适应症。本文简要综述了奥法妥珠单抗在慢性淋巴细胞白血病中的疗效和毒性方面的临床数据。
相似文献
1
Safety and efficacy of ofatumumab in patients with fludarabine and alemtuzumab refractory chronic lymphocytic leukaemia.
Ther Adv Hematol. 2012 Aug;3(4):199-207. doi: 10.1177/2040620712445329.
2
Ofatumumab: a novel anti-CD20 monoclonal antibody for treatment of refractory chronic lymphocytic leukemia.
Ann Pharmacother. 2011 Oct;45(10):1248-55. doi: 10.1345/aph.1P780. Epub 2011 Sep 6.
3
Ofatumumab in the treatment of chronic lymphocytic leukemia.
Drugs Today (Barc). 2010 Jul;46(7):451-61. doi: 10.1358/dot.2010.46.7.1497416.
4
Ofatumumab for the treatment of chronic lymphocytic leukemia.
Expert Rev Hematol. 2015 Jun;8(3):265-72. doi: 10.1586/17474086.2015.1037736. Epub 2015 Apr 16.
5
Ofatumumab as front-line therapy in untreated chronic lymphocytic leukemia.
Future Oncol. 2014 May;10(7):1147-55. doi: 10.2217/fon.14.73.
6
Role of ofatumumab in treatment of chronic lymphocytic leukemia.
J Blood Med. 2011;2:71-7. doi: 10.2147/JBM.S13063. Epub 2011 May 2.
7
The European Medicines Agency review of ofatumumab (Arzerra®) for the treatment of chronic lymphocytic leukemia in patients refractory to fludarabine and alemtuzumab: summary of the scientific assessment of the European medicines agency committee for medicinal products for human use.
Oncologist. 2010;15(12):1335-43. doi: 10.1634/theoncologist.2010-0255. Epub 2010 Dec 14.
8
Ofatumumab for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK.
Health Technol Assess. 2011 May;15 Suppl 1:61-7. doi: 10.3310/hta15suppl1/07.
9
Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia.
Expert Rev Anticancer Ther. 2011 Feb;11(2):151-60. doi: 10.1586/era.10.223.
10
The role of ofatumumab in the treatment of chronic lymphocytic leukemia resistant to previous therapies.
J Blood Med. 2010;1:1-8. doi: 10.2147/JBM.S7284. Epub 2010 Feb 25.
引用本文的文献
1
Sequencing of chronic lymphocytic leukemia therapies.
Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):128-136. doi: 10.1182/asheducation-2016.1.128.
2
Preclinical studies of targeted therapies for CD20-positive B lymphoid malignancies by Ofatumumab conjugated with auristatin.
Invest New Drugs. 2014 Feb;32(1):75-86. doi: 10.1007/s10637-013-9995-y. Epub 2013 Aug 1.
本文引用的文献
1
Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcγRIIIa-genotyped patients with previously treated follicular lymphoma.
Clin Cancer Res. 2012 Mar 1;18(5):1395-403. doi: 10.1158/1078-0432.CCR-11-0850. Epub 2012 Jan 5.
2
Relapsed/refractory diffuse large B-cell lymphoma.
Hematology Am Soc Hematol Educ Program. 2011;2011:498-505. doi: 10.1182/asheducation-2011.1.498.
3
The treatment of relapsed refractory chronic lymphocytic leukemia.
Hematology Am Soc Hematol Educ Program. 2011;2011:110-8. doi: 10.1182/asheducation-2011.1.110.
4
Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia.
Nat Genet. 2011 Dec 11;44(1):47-52. doi: 10.1038/ng.1032.
5
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.
Lancet. 2011 Nov 19;378(9805):1779-87. doi: 10.1016/S0140-6736(11)61649-8. Epub 2011 Oct 31.
6
Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness.
Blood. 2011 Dec 22;118(26):6904-8. doi: 10.1182/blood-2011-08-373159. Epub 2011 Oct 28.
7
Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial.
Arthritis Rheum. 2012 Feb;64(2):350-9. doi: 10.1002/art.33317.
8
Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study.
Blood. 2011 Nov 10;118(19):5126-9. doi: 10.1182/blood-2011-04-348656. Epub 2011 Aug 19.
9
Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells.
J Immunol. 2011 Sep 15;187(6):3438-47. doi: 10.4049/jimmunol.1101189. Epub 2011 Aug 12.
10
Analysis of the coding genome of diffuse large B-cell lymphoma.
Nat Genet. 2011 Jul 31;43(9):830-7. doi: 10.1038/ng.892.
Zotero 插件